| Indicators | Browse All

FibroBiologics, Inc. (FBLG)

Healthcare | Biotechnology | Houston, United States | NasdaqCM
1.44 USD -0.05 (-3.356%) ⇩ (Aug. 28, 2026, 4 p.m. EDT)
After hours: 1.42 -0.02 (-0.020%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT)

Short-term:★★☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | Aug. 22, 2026, 2:37 a.m. EDT

The immediate outlook is clouded by severe structural distress rather than investment opportunity. The company is actively fighting to avoid delisting from Nasdaq, having just announced a reverse stock split to regain compliance with bid price requirements while simultaneously appealing a delisting move. This regulatory precariousness, combined with a massive 58% drop in share price over the last year and a history of negative free cash flow and losses, suggests a high probability of further volatility or a liquidity event rather than a recovery. While the recent price action shows a temporary bounce off the lows, the underlying business fundamentals—negative returns on equity and assets, and no analyst consensus—do not support a bullish thesis. There is no dividend income to offset these risks. Investors should view this as a speculative gamble on a turnaround that faces significant hurdles, not a standard equity investment.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.540748
MSTL0.612507
AutoETS0.624380
AutoARIMA0.631373

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 29%
H-stat 14.72
Ljung-Box p 0.000
Jarque-Bera p 0.059
Excess Kurtosis -0.91
Attribute Value
Sector Healthcare
Debt to Equity Ratio 31.536
Market Cap 9,587,798
Forward P/E -0.44
Beta 1.22
Website https://fibrobiologics.com

Info Dump

Attribute Value
52 Week Change -0.8800322
Address1 455 East Medical Center Boulevard
Address2 Suite 300
All Time High 1,100.0
All Time Low 0.62
Ask 1.46
Ask Size 1
Average Daily Volume10 Day 280,400
Average Daily Volume3 Month 179,377
Average Volume 179,377
Average Volume10Days 280,400
Beta 1.218
Bid 1.0
Bid Size 7
Book Value 0.762
City Houston
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 1.44
Current Ratio 2.643
Custom Price Alert Confidence HIGH
Date Short Interest 1,786,665,600
Day High 1.54
Day Low 1.415
Debt To Equity 31.536
Display Name FibroBiologics
Earnings Timestamp End 1,755,201,600
Earnings Timestamp Start 1,755,201,600
Ebitda -16,466,000
Ebitda Margins 0.0
Enterprise To Ebitda -0.458
Enterprise Value 7,534,798
Eps Current Year -3.0
Eps Forward -3.25
Eps Trailing Twelve Months -4.93
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 0.92284
Fifty Day Average Change 0.51716006
Fifty Day Average Change Percent 0.56040055
Fifty Two Week Change Percent -88.00322
Fifty Two Week High 12.56
Fifty Two Week High Change -11.120001
Fifty Two Week High Change Percent -0.88535035
Fifty Two Week Low 0.62
Fifty Two Week Low Change 0.82000005
Fifty Two Week Low Change Percent 1.3225807
Fifty Two Week Range 0.62 - 12.56
Financial Currency USD
First Trade Date Milliseconds 1,706,711,400,000
Float Shares 6,001,096
Forward Eps -3.25
Forward P E -0.44307694
Free Cashflow -8,368,000
Full Exchange Name NasdaqCM
Full Time Employees 15
Fullday Change -0.05
Fullday Change Percent -3.3557
Fullday Price 1.42
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.09869
Held Percent Institutions 0.15533
Implied Shares Outstanding 6,658,193
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,024-01-31
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,774,828,800
Last Split Factor 1:20
Long Business Summary FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Long Name FibroBiologics, Inc.
Market us_market
Market Cap 9,587,798
Market State CLOSED
Max Age 86,400
Message Board Id finmb_1758633149
Most Recent Quarter 1,782,777,600
Net Income To Common -18,139,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 9,920,707
Number Of Analyst Opinions 2
Open 1.5
Operating Cashflow -14,790,000
Operating Margins 0.0
Payout Ratio 0.0
Phone 281 671 5150
Post Market Change -0.0200001
Post Market Change Percent -1.3888958
Post Market Price 1.42
Post Market Time 1,787,959,806
Previous Close 1.49
Price Eps Current Year -0.48000002
Price Hint 4
Price To Book 1.8897638
Profit Margins 0.0
Quick Ratio 1.588
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.05
Regular Market Change Percent -3.3557
Regular Market Day High 1.54
Regular Market Day Low 1.415
Regular Market Day Range 1.415 - 1.54
Regular Market Open 1.5
Regular Market Previous Close 1.49
Regular Market Price 1.44
Regular Market Time 1,787,947,201
Regular Market Volume 143,715
Return On Assets -0.95765
Return On Equity -6.6008
Sand P52 Week Change 0.20504117
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 6,658,193
Shares Percent Shares Out 0.021300001
Shares Short 141,714
Shares Short Previous Month Date 1,784,073,600
Shares Short Prior Month 70,837
Short Name FibroBiologics, Inc.
Short Percent Of Float 0.0224
Short Ratio 0.93
Source Interval 15
State TX
Symbol FBLG
Target High Price 19.0
Target Low Price 6.0
Target Mean Price 12.5
Target Median Price 12.5
Total Cash 3,515,000
Total Cash Per Share 0.528
Total Debt 1,462,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -4.93
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 3.41217
Two Hundred Day Average Change -1.9721699
Two Hundred Day Average Change Percent -0.5779811
Type Disp Equity
Volume 143,715
Website https://fibrobiologics.com
Zip 77,598